Form 4 for NAMS NewAmsterdam Pharma Co N.V.
Accepted 2025-01-31 00:00:00 ET · period of report 2025-01-29 · accession 0000950170-25-011854 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2025-01-31 | 2025-01-29+ | NAMS | Kling Douglas F | COO | M - OptEx | — | +70.4K | 100.9K | +232% | — |
| DMT | 2025-01-31 | 2025-01-29+ | NAMS | Kling Douglas F | COO | S - Sale+OE | — | -70.4K | 44.0K | -62% | — |
| DMT | 2025-01-31 | 2025-01-29+ | NAMS | Kling Douglas F | COO | M - OptEx | $0.00 | -70.4K | 226.1K | -24% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-01-30 | M | A | 13,578 | — | 57,578 | D | — | — | (F2) The exercise price of the option is 1.16392 euros. |
| 2 | Common | Ordinary Shares | 2025-01-29 | M | A | 56,863 | — | 100,863 | D | — | — | (F2) The exercise price of the option is 1.16392 euros. |
| 3 | Common | Ordinary Shares | 2025-01-30 | S | D | 4,664 | — | 52,914 | D | — | — | (F4) These shares were sold in multiple transactions at prices ranging from $20.33 per share to $21.32 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| 4 | Common | Ordinary Shares | 2025-01-30 | S | D | 8,914 | — | 44,000 | D | — | — | (F5) These shares were sold in multiple transactions at prices ranging from $21.33 per share to $21.93 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| 5 | Common | Ordinary Shares | 2025-01-29 | S | D | 56,863 | — | 44,000 | D | — | — | (F3) These shares were sold in multiple transactions at prices ranging from $20.60 per share to $21.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| 6 | Derivative | Option (right to buy) | 2025-01-29 | M | D | 56,863 | $0.00 | 239,723 | D | — · — to 2031-07-06 | 56,863 Ordinary Shares | (F2) The exercise price of the option is 1.16392 euros. (F6) The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021, which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 121,754 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on March 31, 2022, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |
| 7 | Derivative | Option (right to buy) | 2025-01-30 | M | D | 13,578 | $0.00 | 226,145 | D | — · — to 2031-07-06 | 13,578 Ordinary Shares | (F2) The exercise price of the option is 1.16392 euros. (F6) The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021, which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 121,754 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on March 31, 2022, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |